Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05253560

Prodromal Parkinsonian Features in GBA1 Mutation Carriers

Objective of the trial. To define a sub-population which is at increased risk of developing Parkinson, beyond the fact of carrying Gaucher; in this sub-population the investigators shall conduct a comprehensive evaluation that includes a variety of non-invasive tests, whose purpose is to evaluate the state of the pre- Parkinson's disease signs, signs which can appear, even twenty years before the appearance of the disease, and also to compare them to a group of diagnosed Gaucher patients and a group of healthy people who are not carriers of Gaucher disease.

A group of those carriers will be available for trial or for treatment, if there will be a medicine for the prevention of the development of Parkinson, obtainable.

Recruiting

Interested in participating?

Request Info

Key information

About this study

The carriers, the healthy people and the Gaucher patients will undergo a number of non-invasive tests, which test the pre-Parkinson signs.

The tests are based on various sense tests, blood tests, measuring of blood pressure, lying and standing, ultra-sound of the brain and a neurological test (test of the nervous system and various questionnaires).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing to participate

Exclusion criteria

  • PD patients
  • Dementia

Treatment and study plan

The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.

Diagnostic Test

Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease

Primary outcomes

  1. Building a model to identify carriers of Gaucher disease prone to Parkinson's disease, using tests to assess different domains of PD, including anatomy, cognitive and mental, sleep disorder, and motor.

    Time frame: 8 Years

    Carriers of a variant in the GBA1 gene (GBA carriers) are at the highest risk of developing Parkinson disease (PD). A screening study for prodromal PD features in a cohort of obligatory GBA carriers between 40-75 years was initiated to identify candidates for a PD prevention trial. We added healthy controls and GD patients in order to determine the incidence of prodromal PD and for analyzing the differences between the two groups helping to build a model for identifying at risk PD at the prodromal stage.

    Participants preform 15 pre-defined non-invasive tests for prodromal PD and assessment of risk factors. Risk factors for PD included age, sex, type of GBA1 variant, coffee and tea caffeine consumption, smoking habits, exposure to solvents and pesticides, and family history of PD (1st and/or 2nd degree relatives with PD).

Other outcomes

  1. Transcranial sonography (TCS)

    Time frame: 8 years

    Transcranial sonography (TCS) is a useful noninvasive diagnostic tool to detect hyperechogenicity (SN+) of the substantia nigra area in the brain. The hyperechogenicity happens due to increased amounts of iron, reflecting a functional impairment.

  2. Color discrimination test

    Time frame: 8 years

    Color discrimination was analyzed using The Farnsworth-Munsell 100 hue test. The test includes four boxes with a fixed number of color shade caps with slight shade differences needed to be ordered correctly. The result of each box was entered into a computerized system and automated the total error score (TES)

  3. Hyposmia by the Bit-A UPSIT smell test

    Time frame: 8 years

    The shorter version of the UPSIT smell test (The University of Pennsylvania Smell Identification Test) was used to evaluate hyposmia using twelve cards, each with a different smell.

  4. Orthostatic hypotension (OH)

    Time frame: 8 years

    defined as a fall of at least 20 mmHg systolic or at least ten mmHg diastolic blood pressure by 3 min of active standing or head-up tilt

  5. Montreal Cognitive Assessment (MoCA)

    Time frame: 8 years

    evaluate the cognitive and mental aspects associated with PD. A Montreal Cognitive Assessment (MoCA) score of 26 and above was considered normal

  6. NeuroTrax computerized battery.

    Time frame: 8 years

    The NeuroTrax computerized battery (www.neurotrax.com) includes seven sections: memory, executive function, attention, information processing speed, visual-spatial, verbal function, and motor skills

  7. Beck Depression Inventory

    Time frame: 8 years

    self-administered questioner including 21 questions used to screen, diagnose, and measure the severity of depression.

  8. Frontal lobe assessment battery (FAB).

    Time frame: 8 years

    evaluates executive dysfunction

  9. rapid eye movement (REM)

    Time frame: 8 years

    Idiopathic rapid eye movement sleep behavior disorder is an important risk factor in the diagnosis of PD. The REM questionnaire was completed by the participant.

  10. Epworth sleepiness scale (ESS)

    Time frame: 8 years

    assessing daytime sleepiness includes an eight-question questionnaire scoring between 0 and 24; the higher the score, the higher the chances of dosing off

  11. Perdue pegboard.

    Time frame: 8 years

    Perdue pegboard measures the movement of fingers, hands, and arms in 4 different tasks, testing motor abilities and coordination by placing as many pegs and discs on a board in three 30 seconds trials for each subset and three 60 second trials for the assembly subset

  12. UPDRS part III.

    Time frame: 8 years

    measures gross motor function. A score above 6, not including postural and action tremor, was considered abnormal

  13. The Timed Up and Go (iTUG).

    Time frame: 8 years

    The Timed Up and Go (iTUG) (EncephaLogTM) is a platform that utilizes smartphones' internal motion sensors for conducting motor evaluation including general walking score, step to step persistency, hand sway and rotation time.

  14. Questionnaire regarding risk factors

    Time frame: 8 years

    Spontaneous bowel movement frequency was used to define constipation. Urinary and erectile dysfunction were assessed according to the MDS criteria

Study contacts

Contact information is provided by the study sponsor or research team.

Ari Zimran, MD

CONTACT

[email protected]

+972-509149149

Michal Becker- Cohen, M.Sc.

CONTACT

[email protected]

+972-504606310

Sponsors and collaborators

Lead sponsor

Shaare Zedek Medical Center

Other

Registry information

Important dates

Study start
2017
Primary completion
2030
Study completion
2030
First posted
Feb 24, 2022
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.